Penny$Maker
عضو نشط
- التسجيل
- 11 مارس 2005
- المشاركات
- 496
خذيت 100% اشرايك 
دورة المؤشرنت للتحليل الفني
50 دينار كويتي
dnap
- بادئ الموضوع cmkx
- تاريخ البدء
Penny$Maker
عضو نشط
- التسجيل
- 11 مارس 2005
- المشاركات
- 496
كل واحد وله قرار يختاره انا ان كنت شاريه بسعرك حذفته من سعر 0135 لأني باخذ ربحي وامشي دامي محقق 100% ليش اطمع الطمع يطبع فيه الواحد ويخليك تسوف على الفاضي بس انا ما قولك بيع لأنه عندك هدف وقلتلك انت صاحب القرار وليس أنا وكل واحد يختار
على فكره اخوي انا في كميه مخليها ثابته وفي كميه كل يوم قاعد اضارب فيها على السهم وصحيح كلامك كل واحد وقناعته وطبعا هذا كلامي بس بمنتدى ثاني 
شوفه يمكن تقتنع بوجهه نظري
الشركه مجالها طبي وارتفعت اليوم ارتفاع طيب تقريبا 48% للمتابعه وعلى فكره سعر السهم متذبب يعني شريت اليوم بسعر 0059 وبعت على سعر 0081 مع انه الهاي وصل على نهايه السوق 0092 انشالله باجر اصيدها بسعر حلو طبعا كلامي هذا مو توصيه شراء بس اقولكم تابعو الشركه
وهم هذا بعد
اليوم وصل الهاي 0110 وسكر السوق على 0105 وهم ارد وقولكم موتوصيه شراء بس تابعوها للأمانه انا اليوم اشتغلت عليها مضاربه والحمدالله طلعت بشي طيب وهم اخر شي شريت اسهم وخليتهم حق يوم الاثنين الياي انشالله يستمر على هالحال ويكمل مشواره لي اعلى
فهمتني الحين يعني السهم انا شغال عليه من زمان في كميه لاباس فيها مدخلها بالسهم وكل يوم قاعد اضارب بالسهم واطلع بنسه حلوه علشان جذي مو فارقه معاي ولا كلامك صحيح والقناعه كنز لايفنى
شوفه يمكن تقتنع بوجهه نظري الشركه مجالها طبي وارتفعت اليوم ارتفاع طيب تقريبا 48% للمتابعه وعلى فكره سعر السهم متذبب يعني شريت اليوم بسعر 0059 وبعت على سعر 0081 مع انه الهاي وصل على نهايه السوق 0092 انشالله باجر اصيدها بسعر حلو طبعا كلامي هذا مو توصيه شراء بس اقولكم تابعو الشركه
وهم هذا بعد
اليوم وصل الهاي 0110 وسكر السوق على 0105 وهم ارد وقولكم موتوصيه شراء بس تابعوها للأمانه انا اليوم اشتغلت عليها مضاربه والحمدالله طلعت بشي طيب وهم اخر شي شريت اسهم وخليتهم حق يوم الاثنين الياي انشالله يستمر على هالحال ويكمل مشواره لي اعلى
فهمتني الحين
يعني السهم انا شغال عليه من زمان في كميه لاباس فيها مدخلها بالسهم وكل يوم قاعد اضارب بالسهم واطلع بنسه حلوه علشان جذي مو فارقه معاي ولا كلامك صحيح والقناعه كنز لايفنىPenny$Maker
عضو نشط
- التسجيل
- 11 مارس 2005
- المشاركات
- 496
كلامك 100% مافيه شك ومراح اقول شي الا الله يوفقك فيه ويجعل ربحك زايد متزايد دامك مع سلوك السهم تعرفه ويعرفك لا ملاحظات انت وياه في الميدان والله يهنيك فيك
هذا خوش موقع http://www.americanbulls.com/sitemapotc.asp
خبرين اليوم على السهم
او هذا اول خبر
DNAPrint genomics to Discuss Role of Biological Ancestry In Criminal Investigations at International Web Symposium
SARASOTA, Fla., April 13, 2005 /PRNewswire-FirstCall via COMTEX/ -- DNAPrint(TM) genomics, Inc. (OTC Bulletin Board: DNAP) announced today that the Company will make a presentation covering the role of biological ancestry in criminal investigations at the Human Identification E-Symposium International Web Conference (HumID) at 3:30 p.m. Eastern time on Thursday, April 14.
DNAPrint Forensics Technical Coordinator Zach Gaskin will specifically focus on applying the Company's DNA technology to forensics investigations.
"The worldwide HumID symposium will be an excellent forum for raising awareness among law enforcement officials for our DNAWITNESS(TM) forensics technology," said Mr. Gaskin. "DNAWITNESS(TM) is the only testing method available with predictive capabilities for identifying the percentage of a person's genetic makeup from DNA recovered at a crime scene. And because it narrows the search for potential DNA donors, it can reduce costs and the time needed to identify and question a person of interest."
Law enforcement and forensics professionals can participate in a live question-and-answer session with Mr. Gaskin and other leading industry experts by registering for the conference at http://www.humid.e-symposium.com/speaker-program.php . All presentations and roundtable discussions at the symposium will be archived on the web site for one year. The symposium is sponsored by the Forensic Institute, based in London.
DNAPrint genomics also announced that Mr. Gaskin will discuss the science behind DNAWITNESS(TM) and case studies involving the product's application during a presentation to the Florida Homicide Investigators Association meeting in Cocoa Beach, Fla., on Friday, April 15.
The technology behind DNAWITNESS(TM) has proven useful in allowing forensics investigators to "paint" physical descriptions of a potential crime scene suspect. Using DNA samples lifted from a crime scene, DNAWITNESS(TM) can identify the percentage of a person's genetic makeup among four possible groups -- Sub-Saharan Africa, Native American, East Asian and Indo-European. The recent addition of four additional sub-groups including Northern European, Middle Eastern, Mediterranean and Indo, plus the addition of a predictive test for eye color, make this combined technology unique for criminal detective work.
Mr. Gaskin will describe how DNAWITNESS(TM) assay and associated digital photograph databases constitute a unique forensics product that has been utilized over the past two years in high profile murder cases in the United States, including the Louisiana serial killer and two California slayings -- the Concord Trail Side murder and the Mammoth Lakes murder probe. DNAWITNESS(TM) currently is being utilized in 80 other investigations worldwide.
DNAPrint genomics is continuing to make advances with its technology and recently introduced a DNAWITNESS(TM) test kit, which simplifies the process by enabling forensics experts to conduct their own tests in their own facilities without sending recovered DNA back to the Company for analysis.
About DNAPrint genomics, Inc.
DNAPrint genomics, Inc. uses proprietary human genome research methods to develop genomic-based services and products. The Company's ANCESTRYbyDNA(TM) is a consumer product for individuals interested in learning their family heritage. DNAWitness(TM) is a forensics market tool for analyzing DNA evidence recovered at a crime scene. DNAPrint is also developing products in the pharmacogenomic market including OVANOME(TM), a genomic-based diagnostic tool that matches ovarian cancer patients with the most suitable form and dose of chemotherapy, and STATINOME(TM), a test for the cardiac drug market to determine whether patients will be good or poor responders to statins, which are effective in cholesterol reduction. For more information about the company, please visit http://www.dnaprint.com .
Safe Harbor Provision
All statements in this press release that are not historical are forward- looking statements within the meaning of Section 21E of the Securities Exchange Act as amended. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint genomics, Inc. expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.
او هذا اول خبر
DNAPrint genomics to Discuss Role of Biological Ancestry In Criminal Investigations at International Web Symposium
SARASOTA, Fla., April 13, 2005 /PRNewswire-FirstCall via COMTEX/ -- DNAPrint(TM) genomics, Inc. (OTC Bulletin Board: DNAP) announced today that the Company will make a presentation covering the role of biological ancestry in criminal investigations at the Human Identification E-Symposium International Web Conference (HumID) at 3:30 p.m. Eastern time on Thursday, April 14.
DNAPrint Forensics Technical Coordinator Zach Gaskin will specifically focus on applying the Company's DNA technology to forensics investigations.
"The worldwide HumID symposium will be an excellent forum for raising awareness among law enforcement officials for our DNAWITNESS(TM) forensics technology," said Mr. Gaskin. "DNAWITNESS(TM) is the only testing method available with predictive capabilities for identifying the percentage of a person's genetic makeup from DNA recovered at a crime scene. And because it narrows the search for potential DNA donors, it can reduce costs and the time needed to identify and question a person of interest."
Law enforcement and forensics professionals can participate in a live question-and-answer session with Mr. Gaskin and other leading industry experts by registering for the conference at http://www.humid.e-symposium.com/speaker-program.php . All presentations and roundtable discussions at the symposium will be archived on the web site for one year. The symposium is sponsored by the Forensic Institute, based in London.
DNAPrint genomics also announced that Mr. Gaskin will discuss the science behind DNAWITNESS(TM) and case studies involving the product's application during a presentation to the Florida Homicide Investigators Association meeting in Cocoa Beach, Fla., on Friday, April 15.
The technology behind DNAWITNESS(TM) has proven useful in allowing forensics investigators to "paint" physical descriptions of a potential crime scene suspect. Using DNA samples lifted from a crime scene, DNAWITNESS(TM) can identify the percentage of a person's genetic makeup among four possible groups -- Sub-Saharan Africa, Native American, East Asian and Indo-European. The recent addition of four additional sub-groups including Northern European, Middle Eastern, Mediterranean and Indo, plus the addition of a predictive test for eye color, make this combined technology unique for criminal detective work.
Mr. Gaskin will describe how DNAWITNESS(TM) assay and associated digital photograph databases constitute a unique forensics product that has been utilized over the past two years in high profile murder cases in the United States, including the Louisiana serial killer and two California slayings -- the Concord Trail Side murder and the Mammoth Lakes murder probe. DNAWITNESS(TM) currently is being utilized in 80 other investigations worldwide.
DNAPrint genomics is continuing to make advances with its technology and recently introduced a DNAWITNESS(TM) test kit, which simplifies the process by enabling forensics experts to conduct their own tests in their own facilities without sending recovered DNA back to the Company for analysis.
About DNAPrint genomics, Inc.
DNAPrint genomics, Inc. uses proprietary human genome research methods to develop genomic-based services and products. The Company's ANCESTRYbyDNA(TM) is a consumer product for individuals interested in learning their family heritage. DNAWitness(TM) is a forensics market tool for analyzing DNA evidence recovered at a crime scene. DNAPrint is also developing products in the pharmacogenomic market including OVANOME(TM), a genomic-based diagnostic tool that matches ovarian cancer patients with the most suitable form and dose of chemotherapy, and STATINOME(TM), a test for the cardiac drug market to determine whether patients will be good or poor responders to statins, which are effective in cholesterol reduction. For more information about the company, please visit http://www.dnaprint.com .
Safe Harbor Provision
All statements in this press release that are not historical are forward- looking statements within the meaning of Section 21E of the Securities Exchange Act as amended. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint genomics, Inc. expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.
او هذا الخبرالثاني
DNAPrint genomics Shares Trading Without Interruption Following Erroneous Announcement by NASD of Deletion From Over-the-Counter Bulletin Board
SARASOTA, Fla., April 13, 2005 /PRNewswire-FirstCall via COMTEX/ -- DNAPrint(TM) genomics, Inc. (OTC Bulletin Board: DNAP) stated that an announcement by the National Association of Securities Dealers (NASD) of the deletion of its shares from the Over-the-Counter Bulletin Board was made in error, and that the Company's stock will be trading without interruption today.
DNAPrint genomics said that a Form 15 filing relating to a predecessor company was inadvertently misinterpreted by the NASD, which announced on the OTC BB web site on Tuesday, April 12, that the Company's stock would be deleted from the OTC BB effective today. The NASD immediately withdrew the announcement after the error was brought to its attention.
"The cleanup filing of Form 15 was related to the business of a predecessor company and in no way affects the ongoing operations and corporate status of DNAPrint genomics, Inc.," stated President and Chief Executive Officer Richard Gabriel. "We wish to assure our shareholders that DNAPrint genomics is current with all of its regulatory filings, and we appreciate the NASD's quick corrective action."
About DNAPrint genomics, Inc.
DNAPrint genomics, Inc. uses proprietary human genome research methods to develop genomic-based services and products. The Company's ANCESTRYbyDNA(TM) is a consumer product for individuals interested in learning their family heritage. DNAWitness(TM) is a forensics market tool for analyzing DNA evidence recovered at a crime scene. DNAPrint is also developing products in the pharmacogenomic market including OVANOME(TM), a genomic-based diagnostic tool that matches ovarian cancer patients with the most suitable form and dose of chemotherapy, and STATINOME(TM), a test for the cardiac drug market to determine whether patients will be good or poor responders to statins, which are effective in cholesterol reduction. For more information about the company, please visit http://www.dnaprint.com .
Forward-Looking Statements
All statements in this press release that are not historical are forward- looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint genomics, Inc. expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward- looking statements contained herein to reflect any change in DNAPrint's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.
DNAPrint genomics Shares Trading Without Interruption Following Erroneous Announcement by NASD of Deletion From Over-the-Counter Bulletin Board
SARASOTA, Fla., April 13, 2005 /PRNewswire-FirstCall via COMTEX/ -- DNAPrint(TM) genomics, Inc. (OTC Bulletin Board: DNAP) stated that an announcement by the National Association of Securities Dealers (NASD) of the deletion of its shares from the Over-the-Counter Bulletin Board was made in error, and that the Company's stock will be trading without interruption today.
DNAPrint genomics said that a Form 15 filing relating to a predecessor company was inadvertently misinterpreted by the NASD, which announced on the OTC BB web site on Tuesday, April 12, that the Company's stock would be deleted from the OTC BB effective today. The NASD immediately withdrew the announcement after the error was brought to its attention.
"The cleanup filing of Form 15 was related to the business of a predecessor company and in no way affects the ongoing operations and corporate status of DNAPrint genomics, Inc.," stated President and Chief Executive Officer Richard Gabriel. "We wish to assure our shareholders that DNAPrint genomics is current with all of its regulatory filings, and we appreciate the NASD's quick corrective action."
About DNAPrint genomics, Inc.
DNAPrint genomics, Inc. uses proprietary human genome research methods to develop genomic-based services and products. The Company's ANCESTRYbyDNA(TM) is a consumer product for individuals interested in learning their family heritage. DNAWitness(TM) is a forensics market tool for analyzing DNA evidence recovered at a crime scene. DNAPrint is also developing products in the pharmacogenomic market including OVANOME(TM), a genomic-based diagnostic tool that matches ovarian cancer patients with the most suitable form and dose of chemotherapy, and STATINOME(TM), a test for the cardiac drug market to determine whether patients will be good or poor responders to statins, which are effective in cholesterol reduction. For more information about the company, please visit http://www.dnaprint.com .
Forward-Looking Statements
All statements in this press release that are not historical are forward- looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint genomics, Inc. expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward- looking statements contained herein to reflect any change in DNAPrint's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.
al7bebe
عضو نشط
- التسجيل
- 24 مارس 2005
- المشاركات
- 10,052
قوه ابو فهد
دش هذا الموقع يمكن يعجبكhttp://www.tradersview.com/otcbb_index.htm
واستخدم هذا الموقع في حاله الاق مع الاوسط http://fast.quote.com/fq/stocktrak/livecharts
دش هذا الموقع يمكن يعجبكhttp://www.tradersview.com/otcbb_index.htm
واستخدم هذا الموقع في حاله الاق مع الاوسط http://fast.quote.com/fq/stocktrak/livecharts
al7bebe
عضو نشط
- التسجيل
- 24 مارس 2005
- المشاركات
- 10,052
شوف هذا الموقع يعطيك معلومات وتحليل اكثر عن السهم
http://www.tradersview.com/stock.asp?symbol=AGCC&submit2=Ask!
http://www.tradersview.com/stock.asp?symbol=AGCC&submit2=Ask!
دورة المؤشرنت للتحليل الفني
50 دينار كويتي